Double-layer artificial blood vessel and preparation method thereof

An artificial blood vessel, double-layer technology, applied in the field of functional double-layer artificial blood vessels, can solve the problems of intimal hyperplasia, easy formation of thrombus, calcification, etc., to promote the regulation of inflammatory factor expression, excellent mechanical properties, and promote rapid growth Effect

Active Publication Date: 2019-08-16
ZHONGSHAN HOSPITAL FUDAN UNIV
View PDF12 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] CN104921841A discloses a double-layer artificial blood vessel, which is composed of an inner layer of oriented microfibers and an outer layer of random nanofibers, but the blood vessels prepared by pure synthetic polymer materials have many disadvantages, such as: easy to form thrombus, Intimal hyperplasia, calcification, and chronic inflammation without growth potential
[0005] But so far, there is no report on the preparation of artificial blood vessels by the combination of electrospinning technology and thermal phase separation technology.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Double-layer artificial blood vessel and preparation method thereof
  • Double-layer artificial blood vessel and preparation method thereof
  • Double-layer artificial blood vessel and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] 1) Disperse 50 mg of surface carboxylated mesoporous silicon (MSNs-COOH) into 50 mL of dimethyl sulfoxide (DMSO), and disperse it evenly by ultrasonication;

[0059] 2) Weigh a total amount of 0.8g of EDC and NHS with a molar ratio of 2.5:1 and add them to the above dispersion, and stir at 32°C for 2 hours to activate the carboxyl groups on MSNs-COOH;

[0060] 3) Add 50mL polyethyleneimine (PEI) aqueous solution with a concentration of 80mg / mL dropwise to the carboxyl-activated MSNs-COOH dispersion, first stir for 12 hours, then place in a constant temperature shaker at 37°C for 12 hours, and finally The product was centrifuged, washed with ethanol and deionized water alternately and repeatedly for 3 times, and the product MSNs-PEI was obtained;

[0061] 4) Dissolve 4mg of miRNAs in 15mL of N,N-dimethylformamide (DMF), then add a total of 0.3g of EDC and NHS with a molar ratio of 2.5:1, and stir at 32°C for 2 hours to activate;

[0062] 5) Dispersing the MSNs-PEI prepa...

Embodiment 2

[0069] 1) Disperse 50 mg of surface carboxylated mesoporous silicon (MSNs-COOH) into 50 mL of dimethyl sulfoxide (DMSO), and disperse it evenly by ultrasonication;

[0070] 2) Weigh a total amount of 0.8g of EDC and NHS with a molar ratio of 2.5:1 and add them to the above dispersion, stir at 32°C for 2 hours to activate the carboxyl groups on MSNs-COOH;

[0071] 3) Add 50mL polyethyleneimine (PEI) aqueous solution with a concentration of 80mg / mL dropwise to the MSNs-COOH dispersion with activated carboxyl groups, stir for 12 hours, then put it into a constant temperature shaker at 37°C for 12 hours; finally The product was centrifuged, washed with ethanol and deionized water alternately and repeatedly for 3 times, and the product MSNs-PEI was obtained;

[0072] 4) Dissolve 4mg of miRNAs in 15mL of N,N-dimethylformamide (DMF), then add a total of 0.3g of EDC and NHS with a molar ratio of 2.5:1, and stir at 32°C for 2 hours to activate;

[0073] 5) Dispersing the MSNs-PEI prep...

Embodiment 3

[0080] Test the axial mechanical data of the double-layer artificial blood vessel modified by the mesoporous miRNAs controlled-release nanosphere / heparin compound prepared in Example 1, and the results are shown in the following table:

[0081] Table 1

[0082]

[0083] Test its axial force-deformation diagram as image 3 shown. The first peak point (5.05N, 25.5mm) in the figure is the breaking point of the macroporous layer material obtained by the phase separation of the outer layer, and the second peak point (Peak point) is the breaking point of the inner nanofiber material .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
pore sizeaaaaaaaaaa
pore sizeaaaaaaaaaa
Login to view more

Abstract

The invention discloses a mesoporous miRNAs controlled-release nanosphere / heparin composite modified double-layer artificial blood vessel and a preparation method thereof. An inner layer of the bloodvessel is a mesoporous miRNAs controlled-release nanosphere / heparin composite modified degradable nanofiber layer, and an outer layer is a macroporous nanofiber layer; mesoporous miRNAs controlled-release nanosphere / heparin composite modified degradable nanofibers are spun by fibers, and the fibers are composed of a core layer and a skin layer; the core layer is composed of the components of miRNAs controlled-release nanospheres and heparin, and the skin layer is made of the degradable nanofibers. The functional nanofibers encapsulated with microRNAs controlled-release nanospheres and heparinin the fibers are prepared in the inner layer by a coaxial technology, the inner layer makes contact with blood to achieve the purpose of rapid endothelialization. The outer layer is composed of a macroporous layer prepared by a thermally induced phase separation technology. The double-layer artificial blood vessel provided by the invention has good tissue compatibility and biomechanical properties.

Description

technical field [0001] The present invention relates to a functional double-layer artificial blood vessel, in particular to a novel mesoporous miRNAs controlled-release nanosphere / heparin composite modified double-layer artificial blood vessel based on electrospinning technology and thermal phase separation technology and its preparation method . Background technique [0002] Artificial blood vessels are becoming more and more common in clinical practice. The application of artificial blood vessels with a diameter greater than 6mm is not as problematic as that of small-caliber artificial blood vessels. Small-caliber blood vessels are in great demand in the treatment of cardiovascular diseases such as coronary artery disease and peripheral vascular disease. big. At present, the main problem faced by small-caliber artificial blood vessels is that it is not easy to adjust and match with the surrounding environment of the host, and it is easy to cause thrombus. Through tissue ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L27/40A61L27/20A61L27/18A61L27/54A61L27/50A61L27/58D01D5/34D01F8/14D01F8/16
CPCA61L27/18A61L27/20A61L27/50A61L27/54A61L27/58A61L2300/412A61L2300/42A61L2300/602A61L2400/12D01D5/34D01F8/14D01F8/16C08L5/10C08L67/04C08L75/04
Inventor 陆树洋王春生朱同贺王尧洪涛匡海珠莫秀梅
Owner ZHONGSHAN HOSPITAL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap